Skip to content

Acute Kidney Injury After Cardiac Surgery

Acute Kidney Injury After Cardiac Surgery; A Prospective Randomized Study of Dextran Based and Crystalloid Priming Solutions (PRIMING II Trial)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04293744
Enrollment
100
Registered
2020-03-03
Start date
2020-09-04
Completion date
2023-10-31
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Cardiac Surgical Procedures, Extracorporeal Circulation; Complications

Keywords

Colloid priming solution, Cardiopulmonary bypass, Extracorporeal circulation, ECC, Acute Kidney Injury, AKI

Brief summary

PrimECC is a colloid priming solution for cardiopulmonary bypass/ extracorporeal circulation (ECC) based on Ringers Lactate, supplmeneted with Dextran 40 and Dextran 1. In a previous RCT comparing PrimECC with crystalloid priming fluid, patients in the PrimECC group experienced less hemolysis, less tubular cell injury and beneficial effect on the fluid balance. This study will investigate if, in a population at high risk of acute kidney injury (AKI), priming the ECC circuit with PrimECC instead of crystalloid solution will lead to a reduction of postoperative AKI. The hypothesis is that PrimECC, compared to crystalloid prime, will reduce postoperative AKI. The study is a Swedish multicenter, double-blinded, randomized, controlled clinical trial. The trial will include 366 patients aged ≥18 years, scheduled for cardiac surgery with cardiopulmonary bypass, with an Acute kidney injury risk score ≥30% according to Birnie et al. (2014). The primary outcome of the study is the incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 h or ≥ 50 % increase from baseline) within 96 hours after arrival to the ICU. Secondary outcomes are between-group differences in hemolysis, tubular cell injury (NAG-excretion), estimated GFR, and incidence of AKI of different stages according to the KDIGO creatinine criteria. In addition, differences in CNS (Tau, NFL, NSE, and S100B) and cardiac (TNT/TNI) injury markers will be investigated.

Interventions

DEVICEColloid priming solution for ECC circuit

Prospective, multi-center, double-blinded, randomized, controlled clinical trial

DEVICEStandard priming solution for ECC circuit

Prospective, multi-center, double-blinded, randomized, controlled clinical trial

Sponsors

XVIVO Perfusion
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Has signed and dated the EC approved informed consent * Subject is ≥ 18 years of age * Requires elective or urgent (non-emergency) cardiac procedure requiring the use of ECC. * Preoperative Acute kidney injury risk score ≥30%, found at http://cardiacsurgeryleicester.com/our-research/acute-kidney-injury-risk-score-calculator/

Exclusion criteria

* Unable to give informed consent * Known bleeding disorder * Known intolerance or contraindication to dextran * Acute Surgery (requires emergency cardiac procedure/surgery) * Currently using an antithrombotic medication which has not been discontinued per institution protocol * Malignancy; Surgery within 5 years or ongoing antitumoral treatment * Has ongoing sepsis or endocarditis * Requires pre-operative dialysis

Design outcomes

Primary

MeasureTime frameDescription
Incidence of post-operative AKIWithin 96 hours after ICU arrivalIncidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 hours or ≥ 50 % increase from baseline)

Secondary

MeasureTime frameDescription
NAG excretion1 hour post initiation of ECC, at 1 hour after disconnection from ECC and 24 hours after disconnection from ECC.NAG-excretion (U-NAG/U-creatinine)
eGFRPre-operative and within 96 hours after ICU arrivalpre-operative (day before surgery) compared to the highest post-operative value Measured value of pre-operative eGFR compared to the highest post-operative value within 96 hours after ICU arrival, calculated using the CKD-EPI formula
Incidence of AKIWithin 96 hours after ICU arrivalIncidence of AKI of different stages according to the KDIGO creatinine criteria
CNS injury markersPre-operative (after induction of anesthesia), 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.Measured concentrations of CNS injury markers Tau, NFL, NSE, and S100B
Myocardial injury markersPre-operative (after induction of anesthesia) and at 1 hour after discontinuation of ECC and 24 hours after disconnection from ECC.Measured concentrations of myocardial injury markers TnI or TnT. TnI or TnT is chosen according to institutional standard
HemolysisPre-operative (after induction of anesthesia) and at 1 hour post initiation of ECC, 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.Hemolysis measured as free hemoglobin (PfHb)

Other

MeasureTime frameDescription
Post-operative bleedingThe first 24 hours after disconnection from ECCDrain losses
Post-operative transfusions and use of hemostatic agentsThe first 24 hours after disconnection from ECCTotal transfusions and/or use of erythrocytes, plasma, thrombocytes, hemostatic pharmaceuticals

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026